Politico September 26, 2024
Ruth Reader, Carmen Paun, Daniel Payne and Erin Schumaker

THE REGULATORS

The Food and Drug Administration plans to release new guidance on the use of artificial intelligence in pharmaceutical research.

The new recommendations, slated before the end of the year, follow a consolidation of three AI working groups into one council that will guide the agency’s AI policy work.

The guidance is based in part on responses the agency received to a 2023 discussion paper on the topic. The paper received more than 800 comments from 65 organizations, said Tala Fakhouri, the FDA’s associate director for data science and AI policy.

Between 2016 and 2022, the agency reviewed more than 500 drug submissions in which AI was used.

Fakhouri spoke with Ruth about how the agency is handling the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Interview / Q&A, Technology, Trends
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Trump's Picks for Top Health Jobs Not Just Team of Rivals but 'Team of Opponents'
FDA updates definition of 'healthy'
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients

Share This Article